

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

New Delhi, the 7th October, 2016

ORDER

S.O. 3183(E). In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (6) of the table herein below as the retail price, exclusive of local taxes, if any in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company respectively, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Sl. No.	Name of the Scheduled Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company respectively	Retail Price (Rs.)
1	2	3	4	5	6
1.	Clopidogrel + Rosuvastatin Capsule	Each hard gelatin capsule contains: Clopidogrel Bisulphate eq. to Clopidogrel-75mg (as pellets) Rosuvastatin Calcium eq. to Rosuvastatin-10mg (as pellets)	1 Capsule	M/s Synokem Pharmaceuticals Ltd. & M/s Intas Pharmaceuticals Ltd.	13.94
2.	Clopidogrel + Rosuvastatin Capsule	Each hard gelatin capsule contains: Clopidogrel Bisulphate eq. to Clopidogrel-75mg (as pellets) Rosuvastatin Calcium eq. to Rosuvastatin-5mg (as pellets)	1 Capsule	M/s Synokem Pharmaceuticals Ltd. & M/s Intas Pharmaceuticals Ltd.	10.35
3.	Cholecalciferol Drops (Arbivit-3 Forte)	Each ml contains Cholecalciferol-800 IU (Vitamin D3) Palatable base	1 ml	M/s Raptakos, Brett & Co. Ltd.	4.33

4.	Ceftazidime + Tazobactam Injection (Zytaz-T)	Each vial contains: Ceftazidime Petahydrate eq. to Ceftazidime-1gm (added sterile sodium carbonate as buffering agent) Tazobactam Sodium eq. to Tazobactam-125mg (supplied with 10ml sterile water for injection)	1 Vial	M/s Cadila Healthcare Ltd.	268.45
5.	Glimepiride + Metformin HCl Tablet (Glucoryl M4 Forte)	Each uncoated bilayered tablet contains: Glimepiride-4mg Metformin HCl 1000mg (as sustained release form)	1 Tablet	M/s Windlas Biotech Ltd. & M/s Alkem Laboratories Ltd.	9.45
6.	Tacrolimus Capsule (Tacromus 0.25)	Each hard gelatin capsule contains: Tacrolimus 0.25mg	1 Capsule	M/s Panacea Biotec Ltd. & M/s Cadila Healthcare Ltd.	11.28
7.	Propranolol + Flunarizine Capsule (Migrafina-P)	Each hard gelatin capsule contains: Propranolol HCl-40mg (as sustained release pellets) Flunarizine Dihydrochloride eq. to Flunarizine 10mg (as pellets)	1 Capsule	M/s Innova Captab & M/s Leeford Healthcare Ltd.	8.53

Note :

- (a) The manufacturers of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- (b) The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturers in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturers shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS.
- (d) The above mentioned retail price is applicable only to the individual manufacturers/marketeers as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.

- (e) The concerned manufacturers of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturers, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- (g) Consequent to the issue of retail price of the aforesaid formulations as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand(s) superseded.

PN/169/37/2016/F

F. No. 8(37)/2016/D.P./NPPA-Div.-II

(BALJIT SINGH)
Assistant Director